Outcomes of mitral valve transcatheter edge to edge repair in patients with coronary chronic total occlusion.

IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Future cardiology Pub Date : 2024-11-27 DOI:10.1080/14796678.2024.2434392

Asmaa Ahmed, Mahmoud Eisa, Andrew Takla, Sahej Arora, Mohamed Mohamed, Amir Hanafi, Scott Feitell

{"title":"Outcomes of mitral valve transcatheter edge to edge repair in patients with coronary chronic total occlusion.","authors":"Asmaa Ahmed, Mahmoud Eisa, Andrew Takla, Sahej Arora, Mohamed Mohamed, Amir Hanafi, Scott Feitell","doi":"10.1080/14796678.2024.2434392","DOIUrl":null,"url":null,"abstract":"Introduction: It remains unknown whether the concomitant coronary chronic total occlusion (CTO) would affect the outcomes of the Mitral valve Trans-catheter Edge to edge-to-edge repair (M-TEER) procedure.Methodology: Study population was extracted from the Nationwide Inpatient Sample Data using the International Classification of Diseases and clinical modifications/procedure coding system codes for M-TEER and CTO. Primary outcomes were in-hospital all-cause mortality and net cardiac periprocedural complications. Propensity matching was used to extract a matched control (M-TEER-CTO and M-TEER-No CTO).Results: A total of 48,835 cases of M-TEER were identified in the United States between January 2016 and December 2020, of whom 700 patients (1.5%) had the diagnosis of coronary total occlusion (CTO). The mean age of M-TEER patients was not significantly different between the two groups (76 vs. 75 years, p = 0.11); however, the CTO cohort had a higher percentage of males (66.72% vs. 53.41%, p = 0.002). M-TEER-CTO had higher odds of net all cardiac periprocedural complications (aOR 1.83,95% CI (1.17-2.84), p = 0.007) compared to the no-CTO group, however, there was no difference in in-hospital mortality (aOR 1.54, 95%CI (0.52-4.56), p = 0.43).Conclusions: Patients undergoing M-TEER with CTO had a higher incidence of net all cardiac periprocedural complications but similar mortality compared to those with no CTO.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-5"},"PeriodicalIF":1.6000,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/14796678.2024.2434392","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: It remains unknown whether the concomitant coronary chronic total occlusion (CTO) would affect the outcomes of the Mitral valve Trans-catheter Edge to edge-to-edge repair (M-TEER) procedure.

Methodology: Study population was extracted from the Nationwide Inpatient Sample Data using the International Classification of Diseases and clinical modifications/procedure coding system codes for M-TEER and CTO. Primary outcomes were in-hospital all-cause mortality and net cardiac periprocedural complications. Propensity matching was used to extract a matched control (M-TEER-CTO and M-TEER-No CTO).

Results: A total of 48,835 cases of M-TEER were identified in the United States between January 2016 and December 2020, of whom 700 patients (1.5%) had the diagnosis of coronary total occlusion (CTO). The mean age of M-TEER patients was not significantly different between the two groups (76 vs. 75 years, p = 0.11); however, the CTO cohort had a higher percentage of males (66.72% vs. 53.41%, p = 0.002). M-TEER-CTO had higher odds of net all cardiac periprocedural complications (aOR 1.83,95% CI (1.17-2.84), p = 0.007) compared to the no-CTO group, however, there was no difference in in-hospital mortality (aOR 1.54, 95%CI (0.52-4.56), p = 0.43).

Conclusions: Patients undergoing M-TEER with CTO had a higher incidence of net all cardiac periprocedural complications but similar mortality compared to those with no CTO.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

冠状动脉慢性全闭塞患者二尖瓣经导管边缘修补术的疗效。

导言：冠状动脉慢性全闭塞（CTO）是否会影响二尖瓣经导管边缘至边缘修补术（M-TEER）的疗效仍是一个未知数：研究对象来自全国住院病人抽样数据，使用国际疾病分类和临床修改/程序编码系统中的M-TEER和CTO代码。主要结果为院内全因死亡率和心脏围手术期净并发症。采用倾向匹配法提取匹配对照（M-TEER-CTO 和 M-TEER-无 CTO）：结果：2016年1月至2020年12月期间，美国共发现48835例M-TEER，其中700例患者（1.5%）被诊断为冠状动脉全闭塞（CTO）。两组 M-TEER 患者的平均年龄无明显差异（76 岁对 75 岁，P = 0.11）；但 CTO 组群中男性比例更高（66.72% 对 53.41%，P = 0.002）。与无CTO组相比，M-TEER-CTO组出现所有心脏周围并发症的几率更高（aOR 1.83，95%CI (1.17-2.84)，p = 0.007），但院内死亡率没有差异（aOR 1.54，95%CI (0.52-4.56)，p = 0.43）：结论：与无CTO的患者相比，接受M-TEER手术的CTO患者发生净心脏周围并发症的几率更高，但死亡率相似。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Future cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

2.80

自引率

5.90%

发文量

期刊介绍： Research advances have contributed to improved outcomes across all specialties, but the rate of advancement in cardiology has been exceptional. Concurrently, the population of patients with cardiac conditions continues to grow and greater public awareness has increased patients" expectations of new drugs and devices. Future Cardiology (ISSN 1479-6678) reflects this new era of cardiology and highlights the new molecular approach to advancing cardiovascular therapy. Coverage will also reflect the major technological advances in bioengineering in cardiology in terms of advanced and robust devices, miniaturization, imaging, system modeling and information management issues.